Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer

SIMPLE SUMMARY: The survival of patients with metastatic colorectal cancer (mCRC) has been improved over the years and now reaches 30–40 months. However, few therapeutic options are available after failure of first- and second-line treatments. In fact, prognosis of chemo-refractory mCRC remains poor...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancers (Basel)
Main Authors: Ciardiello, Davide, Martini, Giulia, Famiglietti, Vincenzo, Napolitano, Stefania, De Falco, Vincenzo, Troiani, Teresa, Latiano, Tiziana Pia, Ros, Javier, Elez Fernandez, Elena, Vitiello, Pietro Paolo, Maiello, Evaristo, Ciardiello, Fortunato, Martinelli, Erika
格式: Artigo
語言:Inglês
出版: MDPI 2021
主題:
Review
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073594/
https://ncbi.nlm.nih.gov/pubmed/33920531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081941
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍